Jade Biosciences

JBIO

Valor de mercado US$ 857 mi

Jade Biosciences, Inc. (JBIO) Discusses JADE301 Program Profile and Preclinical Data in Dermatomyositis Transcript

JADE301 is designed to build on a clinically validated IFN-β mechanism with a differentiated profile designed for infrequent subcutaneous dosing JADE301 demonstrated high-affinity, selective IFN-β binding and greater functional potency than a dazukibart comparator in disease-relevant human cells Following subcutaneous administration in non-human primates, JADE301 was effectively half-life extended with an approximately 25-day half-life and predictable distribution into muscle JADE301 was well tolerated in non-human primates at all evaluated subcutaneous doses Phase 1 healthy volunteer trial expected to begin in the fourth quarter of 2026; interim data anticipated in the second half of 2027 Company to host conference call and webcast today at 8:30 a.m. ET SAN FRANCISCO and VANCOUVER, British Columbia, Sept.

Jade Biosciences, Inc. (JBIO) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

SAN FRANCISCO and VANCOUVER, British Columbia, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“Jade” or the “Company”) (Nasdaq: JBIO), a clinical-stage biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced its participation in the following upcoming conferences: Wells Fargo 21st Annual Healthcare Conference Fireside Chat: Tuesday, September 8 at 3:45 p.m.

Jade Biosciences (JBIO) targets IgAN with JADE101, aiming for quarterly dosing that could significantly improve patient adherence versus competitors' more frequent regimens. Phase 1 data show JADE101 achieves ~70% IgA reduction with a favorable safety profile; Phase 2 JUNIPER trial interim data expected in 2027 will be pivotal. JBIO's pipeline includes JADE201 (anti-BAFF-R antibody) and JADE301 (IFN-beta inhibitor), both engineered for extended-interval dosing to differentiate in validated autoimmune markets.

Announced positive interim Phase 1 results for JADE101 demonstrating potential for every 12-week subcutaneous dosing and best-in-class clinical activity in IgA nephropathy  Phase 2 JADE101 clinical trial in IgA nephropathy underway; interim data expected in 2027 Phase 3 JADE101 registrational trial in IgA nephropathy expected to begin in the first half of 2027 Began dosing participants with rheumatoid arthritis in Phase 1 trial of JADE201; interim data expected in 2027 JADE301, a potentially best-in-class, half-life–extended anti-IFN-β for dermatomyositis, now expected to initiate a Phase 1 healthy volunteer trial in the fourth quarter of 2026, with interim data anticipated in second half of 2027 Cash, cash equivalents, and investments of $461 million as of June 30, 2026 expected to provide runway into the fourth quarter of 2028 SAN FRANCISCO and VANCOUVER, British Columbia, Aug. 10, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“Jade” or the “Company”) (Nasdaq: JBIO), a clinical-stage biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced financial results for the second quarter ending June 30, 2026, and provided a corporate update. “This was an important period for Jade as we reported positive interim Phase 1 data for JADE101 that exceeded our expectations across biomarker activity and durability, with a favorable safety profile, strengthening our conviction to rapidly advance the compound to deliver a potentially best-in-class profile in IgA nephropathy,” said Tom Frohlich, Chief Executive Officer of Jade Biosciences.

SAN FRANCISCO and VANCOUVER, British Columbia, June 26, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (the “Company” or “Jade”) (Nasdaq: JBIO), a clinical-stage biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced the appointment of Mark Eisner, M.D., M.P.H., to its Board of Directors, effective June 25, 2026.

SAN FRANCISCO and VANCOUVER, British Columbia, June 05, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“Jade” or the “Company”) (Nasdaq: JBIO), a clinical-stage biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced that it has closed its previously announced public offering of 11,500,000 shares of its common stock, including 1,500,000 shares sold pursuant to the underwriters' full exercise of their option to purchase additional shares. The shares of common stock were sold to the public at a price of $15.00 per share. The gross proceeds to Jade from the offering, before deducting the underwriting discounts and commissions and other offering expenses, were $172.5 million. All of the shares of common stock sold in the public offering were sold by Jade.

SAN FRANCISCO and VANCOUVER, British Columbia, June 03, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“Jade” or the “Company”) (Nasdaq: JBIO), a clinical-stage biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced the pricing of a public offering of 10,000,000 shares of its common stock. The shares of common stock are being sold to the public at a price of $15.00 per share. The gross proceeds to Jade from the offering, before deducting the underwriting discounts and commissions and other offering expenses, are expected to be $150.0 million, excluding any exercise of the underwriters' option to purchase additional shares. The offering is expected to close on June 5, 2026, subject to the satisfaction of customary closing conditions. In addition, Jade has granted the underwriters a 30-day option to purchase up to an additional 1,500,000 shares of common stock at the public offering price, less underwriting discounts and commissions. All of the shares of common stock to be sold in the public offering are being sold by Jade.

SAN FRANCISCO and VANCOUVER, British Columbia, June 03, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“Jade” or the “Company”) (Nasdaq: JBIO), a clinical-stage biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock or, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase shares of its common stock, in a proposed underwritten public offering. All of the shares of common stock and pre-funded warrants to be sold in the proposed offering are being offered by Jade. In addition, Jade intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the securities offered in the public offering, at the public offering price, less underwriting discounts and commissions. There can be no assurance as to whether or when the proposed public offering may be completed, or as to the actual size or terms of the proposed offering.